These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 578665)

  • 41. Outcome following radioactive iodine therapy in Graves' disease.
    Chen JY; Huang HS; Huang MJ; Lin JD; Juang JH; Huang BY; Wang PW; Liu RT
    Changgeng Yi Xue Za Zhi; 1990 Dec; 13(4):258-67. PubMed ID: 2282562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thyroxine replacement in post-radioiodine hypothyroidism.
    Bearcroft CP; Toms GC; Williams SJ; Noonan K; Monson JP
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):115-8. PubMed ID: 2022062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short and long term effects of radioiodine treatment on the iodine content of the thyroid gland.
    Schlumberger M; Fragu P; Hill C; Parmentier C; Tubiana M
    J Clin Endocrinol Metab; 1984 Nov; 59(5):893-8. PubMed ID: 6548226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.
    Markovic V; Eterovic D
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The outcome of treatment with adjusted dose of 131I to thyroid weight for Graves' disease by estimation of effective half life using a single radioiodine uptake measurement].
    Gomi Y; Watanabe M; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Ito K; Suzuki S
    Kaku Igaku; 2000 Mar; 37(2):109-14. PubMed ID: 10783569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radioiodine treatment of Graves' disease - dose/response analysis.
    Cepková J; Horáček J; Vižďa J; Doležal J
    Acta Medica (Hradec Kralove); 2014; 57(2):49-55. PubMed ID: 25257150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.
    Sabri O; Zimny M; Schulz G; Schreckenberger M; Reinartz P; Willmes K; Buell U
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1229-33. PubMed ID: 10199759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [131I-therapy of Basedow's disease and nonimmunogenic hyperthyroidism].
    Hoeschel M; Heinze HG
    Nuklearmedizin; 1984 Jun; 23(3):143-9. PubMed ID: 6548309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A simplified method for treating Graves' disease with radioactive 131I.
    Masri MT; Menne M; Rooney BL; Caplan RH
    Wis Med J; 1995 Jan; 94(1):21-5. PubMed ID: 7871797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Radiotherapy with 131J and 125J of Basedow's disease. Indications and results relative to the incidence of post-actinic hypothyroidism].
    Dradi C; Riceputi G; Biagioli R; Riva P
    Minerva Med; 1979 Jan; 70(2):135-41. PubMed ID: 581903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regime.
    Ratcliffe GE; Fogelman I; Maisey MN
    Br J Radiol; 1986 Nov; 59(707):1105-7. PubMed ID: 3790898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of nuclear medicine in the management of Graves' disease.
    Freitas JE
    Q J Nucl Med; 1999 Dec; 43(4):297-306. PubMed ID: 10731780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 131I therapy and Graves' disease in a long term observation: euthyroidism is a suitable goal. Our experience.
    Montesano T; Toteda M; D'Apollo R; Di Nicola AD; Acqualagna G; Ciancamerla M; Ticconi F; Ugolini F; Filesi M; Ronga G
    Clin Ter; 2014; 165(2):e139-44. PubMed ID: 24770822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intentional radioiodine ablation in Graves' disease.
    Wise PH; Burnet RB; Ahmad A; Harding PE
    Lancet; 1975 Dec; 2(7947):1231-3. PubMed ID: 53722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Five years' experience with iodine-125 therapy of Graves' disease.
    Weidinger P; Johnson PM; Werner SC
    Lancet; 1974 Jul; 2(7872):74-7. PubMed ID: 4136737
    [No Abstract]   [Full Text] [Related]  

  • 59. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
    Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
    J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Possible sequelae of the action of radioactive iodine in man].
    Il'in LA; Arkhangel'skaia GV
    Med Radiol (Mosk); 1973 Aug; 18(8):66-80. PubMed ID: 4801844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.